Inoue K, Masuda N, Iwata H, Takahashi M, et al. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer 2021 Apr 1. pii: 10.1007/s12282-021-01239.
PMID: 33797023